Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
DRAD's Cash to Debt is ranked higher than
85% of the 389 Companies
in the Global Medical Devices industry.

( Industry Median: 3.52 vs. DRAD: No Debt )
DRAD' s 10-Year Cash to Debt Range
Min: 0.56   Max: No Debt
Current: No Debt

Equity to Asset 0.80
DRAD's Equity to Asset is ranked higher than
84% of the 374 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. DRAD: 0.80 )
DRAD' s 10-Year Equity to Asset Range
Min: -1.99   Max: 0.84
Current: 0.8

-1.99
0.84
Interest Coverage 11.40
DRAD's Interest Coverage is ranked higher than
53% of the 207 Companies
in the Global Medical Devices industry.

( Industry Median: 117.58 vs. DRAD: 11.40 )
DRAD' s 10-Year Interest Coverage Range
Min: 0.66   Max: 9999.99
Current: 11.4

0.66
9999.99
F-Score: 9
Z-Score: 2.79
M-Score: -0.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 0.35
DRAD's Operating margin (%) is ranked higher than
61% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 6.09 vs. DRAD: 0.35 )
DRAD' s 10-Year Operating margin (%) Range
Min: -182.88   Max: 0.85
Current: 0.35

-182.88
0.85
Net-margin (%) 0.53
DRAD's Net-margin (%) is ranked higher than
63% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 4.58 vs. DRAD: 0.53 )
DRAD' s 10-Year Net-margin (%) Range
Min: -190.47   Max: 0.87
Current: 0.53

-190.47
0.87
ROE (%) 0.79
DRAD's ROE (%) is ranked higher than
63% of the 370 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. DRAD: 0.79 )
DRAD' s 10-Year ROE (%) Range
Min: -16.03   Max: 1.23
Current: 0.79

-16.03
1.23
ROA (%) 0.64
DRAD's ROA (%) is ranked higher than
66% of the 386 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. DRAD: 0.64 )
DRAD' s 10-Year ROA (%) Range
Min: -58.46   Max: 1.04
Current: 0.64

-58.46
1.04
ROC (Joel Greenblatt) (%) 2.46
DRAD's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 12.53 vs. DRAD: 2.46 )
DRAD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -95.65   Max: 3.45
Current: 2.46

-95.65
3.45
Revenue Growth (%) -4.80
DRAD's Revenue Growth (%) is ranked higher than
58% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. DRAD: -4.80 )
DRAD' s 10-Year Revenue Growth (%) Range
Min: -90.7   Max: 35.4
Current: -4.8

-90.7
35.4
» DRAD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

DRAD Guru Trades in Q3 2013

Jim Simons 758,800 sh (+0.53%)
» More
Q4 2013

DRAD Guru Trades in Q4 2013

Jim Simons 835,400 sh (+10.09%)
» More
Q1 2014

DRAD Guru Trades in Q1 2014

Jim Simons 844,761 sh (+1.12%)
» More
Q2 2014

DRAD Guru Trades in Q2 2014

Jim Simons 889,030 sh (+5.24%)
» More
» Details

Insider Trades

Latest Guru Trades with DRAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 16.20
DRAD's P/E(ttm) is ranked higher than
93% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 60.50 vs. DRAD: 16.20 )
DRAD' s 10-Year P/E(ttm) Range
Min: 15.36   Max: 202.11
Current: 16.2

15.36
202.11
P/B 1.90
DRAD's P/B is ranked higher than
79% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 3.39 vs. DRAD: 1.90 )
DRAD' s 10-Year P/B Range
Min: 0.19   Max: 3.12
Current: 1.9

0.19
3.12
P/S 1.20
DRAD's P/S is ranked higher than
77% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. DRAD: 1.20 )
DRAD' s 10-Year P/S Range
Min: 0.02   Max: 1.99
Current: 1.2

0.02
1.99
PFCF 18.70
DRAD's PFCF is ranked higher than
91% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. DRAD: 18.70 )
DRAD' s 10-Year PFCF Range
Min: 0.13   Max: 353
Current: 18.7

0.13
353
EV-to-EBIT 10.43
DRAD's EV-to-EBIT is ranked higher than
96% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 57.20 vs. DRAD: 10.43 )
DRAD' s 10-Year EV-to-EBIT Range
Min: 10.1   Max: 1991.6
Current: 10.43

10.1
1991.6
Current Ratio 4.25
DRAD's Current Ratio is ranked higher than
80% of the 246 Companies
in the Global Medical Devices industry.

( Industry Median: 2.86 vs. DRAD: 4.25 )
DRAD' s 10-Year Current Ratio Range
Min: 1.03   Max: 5.53
Current: 4.25

1.03
5.53
Quick Ratio 3.79
DRAD's Quick Ratio is ranked higher than
83% of the 246 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. DRAD: 3.79 )
DRAD' s 10-Year Quick Ratio Range
Min: 0.88   Max: 4.82
Current: 3.79

0.88
4.82

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 5.70
DRAD's Dividend Yield is ranked higher than
96% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 1.22 vs. DRAD: 5.70 )
DRAD' s 10-Year Dividend Yield Range
Min: 1.3   Max: 4.67
Current: 5.7

1.3
4.67
Dividend Payout 0.72
DRAD's Dividend Payout is ranked higher than
78% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. DRAD: 0.72 )
DRAD' s 10-Year Dividend Payout Range
Min: 1.25   Max: 1.28
Current: 0.72

1.25
1.28
Yield on cost (5-Year) 5.70
DRAD's Yield on cost (5-Year) is ranked higher than
95% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 1.32 vs. DRAD: 5.70 )
DRAD' s 10-Year Yield on cost (5-Year) Range
Min: 1.3   Max: 4.67
Current: 5.7

1.3
4.67
Share Buyback Rate -0.70
DRAD's Share Buyback Rate is ranked higher than
80% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: -1.10 vs. DRAD: -0.70 )
DRAD' s 10-Year Share Buyback Rate Range
Min: 0.1   Max: -1314
Current: -0.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.90
DRAD's Price/Net Cash is ranked higher than
96% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. DRAD: 4.90 )
DRAD' s 10-Year Price/Net Cash Range
Min: 0.68   Max: 5.62
Current: 4.9

0.68
5.62
Price/Net Current Asset Value 3.30
DRAD's Price/Net Current Asset Value is ranked higher than
95% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. DRAD: 3.30 )
DRAD' s 10-Year Price/Net Current Asset Value Range
Min: 0.43   Max: 3.73
Current: 3.3

0.43
3.73
Price/Tangible Book 2.30
DRAD's Price/Tangible Book is ranked higher than
81% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 5.80 vs. DRAD: 2.30 )
DRAD' s 10-Year Price/Tangible Book Range
Min: 0.23   Max: 2.77
Current: 2.3

0.23
2.77
Price/DCF (Projected) 2.00
DRAD's Price/DCF (Projected) is ranked higher than
80% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. DRAD: 2.00 )
DRAD' s 10-Year Price/DCF (Projected) Range
Min: 1.1   Max: 2.93
Current: 2

1.1
2.93
Price/Median PS Value 1.50
DRAD's Price/Median PS Value is ranked lower than
54% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. DRAD: 1.50 )
DRAD' s 10-Year Price/Median PS Value Range
Min: 0.02   Max: 2.41
Current: 1.5

0.02
2.41
Price/Graham Number 1.30
DRAD's Price/Graham Number is ranked higher than
90% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 7.20 vs. DRAD: 1.30 )
DRAD' s 10-Year Price/Graham Number Range
Min: 1.35   Max: 10.23
Current: 1.3

1.35
10.23
Earnings Yield (Greenblatt) 9.40
DRAD's Earnings Yield (Greenblatt) is ranked higher than
90% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. DRAD: 9.40 )
DRAD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 9.9
Current: 9.4

0.1
9.9
Forward Rate of Return (Yacktman) 0.85
DRAD's Forward Rate of Return (Yacktman) is ranked higher than
74% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 1.36 vs. DRAD: 0.85 )
DRAD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -8.1   Max: 1.1
Current: 0.85

-8.1
1.1

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Digirad Corporation was incorporated in Delaware in 1997. The Company is a developer and manufacturer of medical diagnostic imaging systems including solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications. It is a national provider of in-office nuclear cardiology imaging and ultrasound services to physician practices, hospitals and imaging centers through its Digirad Imaging Solutions ("DIS") business segment. The Company designed and commercialized the first solid-state nuclear gamma camera for the detection of cardiovascular disease and other medical conditions. Its imaging systems are sold in both portable and fixed configurations, and provide enhanced operability, improved patient comfort and, in the case of its triple-headed Cardius 3 XPO system, shorter image acquisition time when compared to traditional vacuum tube cameras or its single or dual headed cameras. The Company's nuclear cameras fit easily into floor spaces as small as seven feet by eight feet and facilitate the delivery of nuclear medicine procedures in a physician's office, an outpatient hospital setting or within multiple departments of a hospital, (e.g., emergency and operating rooms). Its two operating segments are: DIS and Diagnostic Imaging. Through DIS, it offers a diagnostic imaging services program as an alternative to purchasing a gamma camera or ultrasound equipment for physicians who wish to perform nuclear imaging, echocardiography, vascular ultrasound, or any combination of these procedures in their offices by leasing the imaging system, certified personnel and other support required to perform imaging in the physician's office. The target market for its products and services is comprised of cardiologists, internal medicine physicians, family practice physicians, and hospitals in the United States that perform or could perform nuclear and ultrasound diagnostic imaging procedures. During the year ended December 31, 2012, the company provided imaging services through DIS to more than 475 physicians and physician groups. The Company has sold over 700 cameras through its Diagnostic Imaging segment. The Company and its medical professionals are subject to federal and state laws and regulations.
» More Articles for DRAD

Headlines

Articles On GuruFocus.com
Top 3 Insider Buys Highlighted by Energy Companies Jul 12 2013 
DRAD Directors Increase Their Stake in the Medical Supply Company Apr 25 2013 
Expansion Initiates Insider Buying for NTS Apr 11 2013 
Digirad Corp. Reports Operating Results (10-K/A) Jul 30 2010 
Digirad Corp. Reports Operating Results (10-Q) Jul 29 2010 
Digirad Corp. Reports Operating Results (10-Q) Apr 29 2010 
Digirad Corporation Q3 2009 update Oct 29 2009 
Miguel Barbosa Interviews Famous Blogger, Greenbackd! Oct 29 2009 
Digirad Corp. Reports Operating Results (10-Q) Oct 22 2009 
Digirad Corporation Reports Fourth Quarter and Full Year 2008 Financial Results Feb 05 2009 

More From Other Websites
Nasdaq stocks posting largest volume increases Aug 19 2014
DIGIRAD CORP Financials Aug 09 2014
DIGIRAD CORP Files SEC form 10-Q, Quarterly Report Aug 04 2014
Digirad Corporation Reports Financial Results for Second Quarter and First Six Months of 2014 Aug 01 2014
DIGIRAD CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 01 2014
Digirad Corporation Reports Financial Results for Second Quarter and First Six Months of 2014 Aug 01 2014
Digirad Corporation to Release 2014 Second Quarter and Six Month Financial Results on August 1, 2014 Jul 14 2014
Digirad Corporation to Release 2014 Second Quarter and Six Month Financial Results on August 1, 2014 Jul 14 2014
Lone Star reports 5.2% stake in Digirad Corp May 14 2014
DIGIRAD CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 13 2014
DIGIRAD CORP Files SEC form 10-Q, Quarterly Report May 02 2014
DIGIRAD CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 01 2014
Digirad Buys Telerhythmics Mar 21 2014
DIGIRAD CORP Files SEC form 10-K, Annual Report Mar 20 2014
Digirad: Why I No Longer Like The Short Side Mar 19 2014
Digirad Corporation to Release 2013 Fourth Quarter and Year-End Financial Results on February 26,... Mar 18 2014
Digirad Corporation Reports Fourth Quarter and Year-End Financial Results Mar 18 2014
Digirad Acquires Telerhythmics Mar 18 2014
DIGIRAD CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Mar 14 2014
Digirad Management Discusses Q4 2013 Results - Earnings Call Transcript Feb 26 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide